Nexara Health — Health Canada Drug Establishment Licence #3-002896

TARO-WARFARIN 1 MG

Last verified 2026-09-10 · Source: Health Canada Drug Product Database (DPD), DIN 02242680

TARO-WARFARIN 1 MG — DIN 02242680

WARFARIN SODIUM : 1 MG · TARO PHARMACEUTICALS INC · TABLET · wholesale supply in Canada

Health Canada status: MARKETED

What is TARO-WARFARIN?

TARO-WARFARIN 1 MG contains WARFARIN SODIUM : 1 MG. It is listed in the Health Canada Drug Product Database under DIN 02242680, held by TARO PHARMACEUTICALS INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 09-Aug-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is TARO-WARFARIN used for?

Prophylaxis/treatment of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization; adjunct in prophylaxis of systemic embolism after MI (stroke/reinfarction).

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Warfarin cost around the world?

Warfarin is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Hungary publishes a producer price (ex-factory); Italy publishes a prezzo al pubblico (classe A). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
United Statesacquisition993USD███.██
Australiaex-manufacturer26AUD███.██
Hungaryproducer price (ex-factory)66HUF███.██
United Kingdomhospital44GBP███.██
Italyprezzo al pubblico (classe A)11EUR███.██

110 pack listings across 22 brand entries and 5 price bases, refreshed 08 Sep 2026. Ranges span every Warfarin pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Warfarin in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

8 holders have a Canadian DIN containing Warfarin, across 60 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
TARO PHARMACEUTICALS INC99TARO-WARFARINSourceable in Canada
APOTEX INC77APO-WARFARINSourceable in Canada
BRISTOL-MYERS SQUIBB CANADA90COUMADIN, COUMADIN TAB 10MG, COUMADIN TAB 1MG, COUMADIN TAB 2.5MG, COUMADIN TAB 2MG, +4 moreNo marketed DIN
MYLAN PHARMACEUTICALS ULC90MYLAN-WARFARINNo marketed DIN
NOVOPHARM LIMITED90NOVO-WARFARINNo marketed DIN
SANIS HEALTH INC90WARFARINNo marketed DIN
NU-PHARM INC70NU-WARFARINNo marketed DIN
MERCK FROSST CANADA & CIE, MERCK FROSST CANADA & CO.10WARFILONE TAB 5MGNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label1 MG
Dosage formTABLET
RouteORAL
Pack configuration (monograph)Not explicitly detailed in provided text (mentions 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg strengths).
StorageNot specified in the provided text.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceWarfarin
ATC codeB01AA03
AHFS class20:12.04.08
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02242680
DIN (unpadded, as printed on some documents)2242680
Brand nameTARO-WARFARIN
Generic / active ingredientWARFARIN SODIUM : 1 MG
Market authorization holderTARO PHARMACEUTICALS INC
Health Canada schedulePrescription
ATC codeB01AA03
ATC anatomical main groupB — Blood and blood-forming organs
ATC therapeutic subgroupB01AA
Current statusMARKETED
Status date09-Aug-2000
Original market date2000-08-09 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

How is it administered?

Individualized based on PT/INR. Initial dose usually 2-5 mg/day. Maintenance 2-10 mg/day. Monitor INR regularly. Adjust for elderly or hepatic impairment.

Included because it drives pack selection and wastage. Consult the monograph.

Contraindications

Pregnancy; haemorrhagic tendencies; recent CNS/eye surgery; active GI/GU/respiratory ulceration; cerebral aneurysms; bacterial endocarditis; malignant hypertension; hypersensitivity.

Warnings and precautions

Major or fatal bleeding risk. Tissue necrosis/gangrene. Calciphylaxis. Systemic atheroemboli/cholesterol microemboli. Narrow therapeutic index; requires regular INR monitoring.

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

16 of 60 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
APO-WARFARIN10 MGTABLETAPOTEX INCMARKETED02242929
APO-WARFARIN2 MGTABLETAPOTEX INCMARKETED02242925
APO-WARFARIN2.5 MGTABLETAPOTEX INCMARKETED02242926
APO-WARFARIN5 MGTABLETAPOTEX INCMARKETED02242928
APO-WARFARIN3 MGTABLETAPOTEX INCMARKETED02245618
APO-WARFARIN4 MGTABLETAPOTEX INCMARKETED02242927
APO-WARFARIN1 MGTABLETAPOTEX INCMARKETED02242924
TARO-WARFARIN3 MGTABLETTARO PHARMACEUTICALS INCMARKETED02242683
TARO-WARFARIN5 MGTABLETTARO PHARMACEUTICALS INCMARKETED02242685
TARO-WARFARIN7.5 MGTABLETTARO PHARMACEUTICALS INCMARKETED02242697

2 · Same class — other molecules in ATC B01AA

MoleculeCanadian brandsDINsMarketedSourceable
WarfarinAPO-WARFARIN · COUMADIN · COUMADIN TAB 10MG · COUMADIN TAB 1MG · +12 more6016Yes
AcenocoumarolSINTROM20Not in Canada

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC B01A

ATC subgroupMoleculesDINsMarketed
B01AFApixaban · Edoxaban · Rivaroxaban159121
B01ABAntithrombin · Dalteparin · Danaparoid · Enoxaparin · Heparin · +3 more12882
B01ACAbciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more15866
B01AEArgatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin1811
B01AXCaplacizumab · Defibrotide · Fondaparinux105
B01ADAlteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more224

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is TARO-WARFARIN called?

The same molecule, Warfarin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
CoumadinLatinAustralia
MarevanLatinAustralia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for TARO-WARFARIN

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Related pages

Sourcing this product